Form 4: Aerovate Therapeutics' Chief Medical Officer Reports Stock Transactions
SEC Form 4 Filing
Hunter Gillies, Chief Medical Officer of Aerovate Therapeutics, reports the sale of common stock and exercise of stock options under a pre-arranged trading plan.
Summary
- On April 17, 2024, Hunter Gillies, the Chief Medical Officer of Aerovate Therapeutics, executed transactions involving the company's common stock.
- Gillies exercised stock options to acquire 4,000 shares at a price of $1.74 per share.
- He then sold 3,689 shares at a weighted average price of $22.3006, with individual sales ranging from $22.08 to $22.80.
- Additionally, he sold 311 shares at a weighted average price of $23.3277, with individual sales ranging from $23.12 to $23.97.
- These transactions were conducted under a Rule 10b5-1 trading plan adopted on January 19, 2023.
- Following these transactions, Gillies directly owns 3,251 shares of common stock.
- Gillies also owns options to purchase 3,050 shares of common stock.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions by a company executive. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company executives.
Comparison to Industry Standards
- Form 4 filings are standard practice for publicly traded companies in the US, ensuring transparency of insider trading activities.
- The Rule 10b5-1 trading plan is a common tool used by executives to avoid accusations of insider trading, similar to plans used by executives at companies like Pfizer or Moderna.
- The vesting schedules of the stock options are typical for employee compensation packages in the biotechnology industry, comparable to those offered by companies like Amgen or Biogen.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership, but the effect is likely minimal given the relatively small number of shares involved.
- The transactions do not directly impact employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| January 19, 2023 | Date the Reporting Person adopted the Rule 10b5-1 trading plan |
| September 4, 2020 | Date of grant for employee stock options |
| April 17, 2024 | Date of the reported transactions (exercise of options and sale of stock) |
| April 19, 2024 | Date of signature for the Form 4 filing |
| September 3, 2030 | Expiration date of the stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.